Puberty blockers are an "unregulated live experiment" on adolescents, with "likely permanent" impacts on cognitive function in animals.

The Karolinska Institute has stopped giving puberty blockers to adolescents under 16. The Institute cites uncertain and extensive adverse health consequences, and the difficulties gaining informed consent.

NICE have published a review of the evidence for puberty blockers. They report little or no change in mental health outcomes and a "very low" certainty of evidence.

Many experts believe that puberty supression could have irreversible and detrimental impacts.

NAPP advise that gender dysphoria can often be a manifestation of pre-existing family, social or psychiatric conditions. Conditions should be treated first before puberty blockers are considered.

The ICGP have removed statements describing puberty blockers as "reversible" from their guidelines. They now emphasise psychotherapy and highlight the lack of evidence for blockers

The RANZCP advise their members that there is a "paucity of quality evidence" on outcomes for children with gender dysphoria.

Finland has published advice on the medical treatment of gender dysphoric minors that contradicts New Zealand's Ministry of Health.

The CEBM reviewed the research on puberty blockers and highlights blockers as a "momentous step in the dark".

The NHS has removed language indicating blockers are "fully reversible" and now states that it is "not known whether hormone blockers affect the development of the teenage brain or children's bones"